Anzeige
Meldung des Tages: Der nächste Gold-Hebel? 200 Meter Treffer, volle Kassen – warum diese Aktie jetzt auffällt

Kodiak Sciences Aktie News

Aktie
WKN:  A2N6P0 ISIN:  US50015M1099 US-Symbol:  KOD Branche:  Biotechnologie Land:  USA
22,77 €
+0,07 €
+0,31%
07:17:06 Uhr
Depot/Watchlist
Marktkapitalisierung *
1,34 Mrd. €
Streubesitz
17,62%
KGV
-6,62
Index-Zuordnung
-

Kodiak Sciences News

07.01.26 - PR Newswire
Kodiak Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference
Kodiak Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference PR Newswire
18.12.25 - PR Newswire
Kodiak Sciences Announces Closing of $184 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares
Kodiak Sciences Announces Closing of $184 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares PR Newswire
16.12.25 - PR Newswire
Kodiak Sciences Announces Pricing of Upsized Public Offering of Common Stock
Kodiak Sciences Announces Pricing of Upsized Public Offering of Common Stock PR Newswire
15.12.25 - PR Newswire
Kodiak Sciences Announces Proposed Public Offering of Common Stock
Kodiak Sciences Announces Proposed Public Offering of Common Stock PR Newswire
13.11.25 - PR Newswire
Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2025 Financial Results
Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2025 Financial Results PR Newswire
12.11.25 - PR Newswire
Kodiak Sciences to Present at Upcoming Investor Conferences
Kodiak Sciences to Present at Upcoming Investor Conferences PR Newswire
05.11.25 - PR Newswire
Follow-up data for Kodiak's KSI-101 from the APEX study showed continued strengthening of clinical effect (≥90% of patients achieving absence of intraretinal and subretinal fluid) through week 20 in macular edema secondary to inflammation (MESI)
Follow-up data for Kodiak's KSI-101 from the APEX study showed continued strengthening of clinical effect (≥90% of patients achieving absence of intraretinal and subretinal fluid) ...
15.09.25 - PR Newswire
New data for Kodiak's KSI-101 from the APEX study reinforce its clinically meaningful vision gains and rapid retinal drying in macular edema secondary to inflammation (MESI)
New data for Kodiak's KSI-101 from the APEX study reinforce its clinically meaningful vision gains and rapid retinal drying in macular edema secondary to inflammation (MESI) PR ...
02.09.25 - PR Newswire
Kodiak Sciences to Participate in Upcoming Scientific Conferences Highlighting KSI-101 in Patients with Macular Edema Secondary to Inflammation (MESI)
Kodiak Sciences to Participate in Upcoming Scientific Conferences Highlighting KSI-101 in Patients with Macular Edema Secondary to Inflammation (MESI) PR Newswire
19.08.25 - PR Newswire
Kodiak Sciences to Present at American Chemical Society Fall 2025
Kodiak Sciences to Present at American Chemical Society Fall 2025 PR Newswire
13.08.25 - PR Newswire
Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2025 Financial Results
Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2025 Financial Results PR Newswire
10.07.25 - PR Newswire
Kodiak Sciences to Host Investor R&D Day on July 16, 2025
Kodiak Sciences to Host Investor R&D Day on July 16, 2025 PR Newswire
25.06.25 - PR Newswire
Kodiak Sciences to Present KSI-101 Highlights at 2025 Congress of the International Ocular Inflammation Society
Kodiak Sciences to Present KSI-101 Highlights at 2025 Congress of the International Ocular Inflammation Society PR Newswire
29.05.25 - PR Newswire
Kodiak Sciences to Present at 2025 Jefferies Global Healthcare Conference
Kodiak Sciences to Present at 2025 Jefferies Global Healthcare Conference PR Newswire
14.05.25 - PR Newswire
Kodiak Sciences Announces Recent Business Highlights and First Quarter 2025 Financial Results
Kodiak Sciences Announces Recent Business Highlights and First Quarter 2025 Financial Results PR Newswire
01.05.25 - PR Newswire
Kodiak Sciences Data at ARVO 2025 Highlight Power and Versatility of ABC Platform in Addressing Complex Multifactorial Ocular Diseases
Kodiak Sciences Data at ARVO 2025 Highlight Power and Versatility of ABC Platform in Addressing Complex Multifactorial Ocular Diseases PR Newswire
27.03.25 - PR Newswire
Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results PR Newswire
10.03.25 - PR Newswire
Kodiak Sciences Completes Enrollment in Second Registrational Trial of Tarcocimab in Patients with Diabetic Retinopathy
Kodiak Sciences Completes Enrollment in Second Registrational Trial of Tarcocimab in Patients with Diabetic Retinopathy PR Newswire
04.02.25 - PR Newswire
Kodiak Sciences to Present at Glaucoma 360 New Horizons Forum 2025
Kodiak Sciences to Present at Glaucoma 360 New Horizons Forum 2025 PR Newswire
26.01.25 - Boersia.de
Kodiak Sciences Aktie: Auf holprigem Kurs!
Die Aktie des Biopharma-​Unternehmens Kodiak Sciences verzeichnete am 25. Januar 2025 einen moderaten Anstieg von 0,79 Prozent auf 7,63 EUR. Diese positive Entwicklung ...

Newssuche

Videos

newspaper
20.01.26 +2,43%
Technical Trading: Gold Zukauf
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »